A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

Abstract Background Escalating healthcare costs are necessitating the practice of value-based oncology. It is crucial to critically evaluate the economic impact of influential but expensive therapies such as immune checkpoint inhibitors (ICIs). To date, no systematic assessment of the cost-effective...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Vivek Verma, Tanja Sprave, Waqar Haque, Charles B. Simone, Joe Y. Chang, James W. Welsh, Charles R. Thomas
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2018-11-01
Collection:Journal for ImmunoTherapy of Cancer
Sujets:
Cost-effectiveness
Value
Immunotherapy
Immune checkpoint inhibitor
Public policy
Public health
Accès en ligne:http://link.springer.com/article/10.1186/s40425-018-0442-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires